Avenacy Launched Leuprolide Acetate Injection in the U.S.
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Leuprolide Acetate Injection in the United States.
Pharmaceutical, BioTech Product Launches and Technology Innovations
OmniAb introduces the xPloration® Partner Access Program to the market
OmniAb, Inc. the launch of the xPloration Partner Access Program, under which current OmniAb partners can purchase the xPloration instrument to significantly enhance their capabilities in antibody discovery and development. xPloration is OmniAb’s proprietary, innovative, high-throughput single B-cell screening platform that leverages machine learning and artificial intelligence.
Low Nitrite METHOCEL™ HPMC for Nitrosamine Mitigation Launched by IFF Pharma Solutions
IFF Pharma Solutions, a global leader in polymer innovations, announced the launch of Low Nitrite METHOCEL™ hydroxypropyl methylcellulose (HPMC), a range of low nitrite cellulose ethers developed to reduce the risk of nitrosamine formation in finished pharmaceutical dosages.
Launch of Propofol Injectable Emulsion, USP in the U.S. Market Announced by Avenacy
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Propofol Injectable Emulsion, USP in the United States as a therapeutic generic equivalent for Diprivan® as approved by the U.S. Food and Drug Administration.
Hanmi Pharmaceutical's 'Gugutams' will be launched in Mexico as 'Aditams', marking the beginning of a full-scale expansion into Latin America
Hanmi Pharmaceutical's combination therapy for Obstructive Prostatic Growth (OPG) caused by Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED), Gugutams, is entering the Mexican market under the local brand name "Aditams."